Clinical trial · Interventional
Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer
NCT01206218CI-TRIAL-00003939BREC-AGCunknownPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation of customized treatment according to BRCA1 assessment in patients with advanced gastric cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FLO Regimen or FLOT Regimen | Drug | — | UNRESOLVED |
| FLOT Regimen | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Group A
- description
- FLOT Regimen
- interventionNames
- Drug: FLOT Regimen
- type
- EXPERIMENTAL
- label
- Group B
- description
- FLO Regimen or FLOT Regimen
- interventionNames
- Drug: FLO Regimen or FLOT Regimen
Primary outcomes (1)
- measure
- Progression-free Survival
- timeFrame
- 12 months
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Provision of informed consent * Female or male aged 18 years and over * Histologic or cytologic confirmation of advanced gastric cancer * Stage III-IV (AJCC 7th) * ECOG: 0-2 * Have tumor sample that can be tested for BRCA1 mRNA expression * Negative pregnancy test for women of childbearing potential * Neutrophile granulocyte greater than 1.5×10\^9/L * Hemoglobin greater than 10g/dL * Platelet greater than 100×10\^9/L * Serum bilirubin not greater than 1.5x upper limit of reference range (ULRR) * ALT or AST not greater than 1.5x ULRR * Creatinine clearance no less than 60ml/min Exclusion Criteria: * Have at least another primary malignant tumor * Active infection * Chemotherapy with experimental drug within 3 weeks before the start of study therapy * Women who are pregnant or breast feeding * Weight loss greater 10% within 6 weeks before the start of study therapy
References
Publications (0)
Data not yet available
No reference posted for this study.